Literature DB >> 8349777

Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.

M A Pfaller1, A L Barry, P C Fuchs.   

Abstract

Levofloxacin disk susceptibility test criteria were evaluated by testing 350 bacterial isolates. Either 5- or 10-micrograms disks could be used satisfactorily. A 5-micrograms levofloxacin disk with zone size breakpoints of < or = 12 mm for resistance (MIC, > or = 8.0 micrograms/ml) and > or = 16 mm for susceptibility (MIC, < or = 2.0 micrograms/ml) is recommended.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8349777      PMCID： PMC265662          DOI： 10.1128/jcm.31.7.1924-1926.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens.

Authors:  C E Cherubin; R H Eng; S M Smith; E N Tan
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

2.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Proposed disk diffusion susceptibility criteria for ofloxacin.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

5.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

7.  In vitro activity of l-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci.

Authors:  B Foleno; K P Fu
Journal:  Diagn Microbiol Infect Dis       Date:  1992-08       Impact factor: 2.803

8.  Enantioselective disposition of ofloxacin in humans.

Authors:  O Okazaki; C Kojima; H Hakusui; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; T L Gavan
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

10.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191
View more
  7 in total

1.  Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI Breakpoints.

Authors:  Romney M Humphries; Janet A Hindler; Keith Shaffer; Shelley A Campeau
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

2.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.

Authors:  A Barry; P Fuchs; F Tenover; S Allen; D Hardy; J Jorgensen; J McLaughlin; L Reller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

4.  Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

5.  Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.

Authors:  M G Cormican; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

6.  Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

Authors:  L D Sutton; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 7.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.